Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation

Gemma E. White · Andrew Cotterill ·
Mark R. Addley · Elizabeth J. Soilleux ·
David R. Greaves

Abstract Treatment of cells with cytokines and growth factors leads to the synthesis of Suppressor of Cytokine Signalling (SOCS) proteins that act as potent negative regulators of signalling via the Jak/STAT pathway. We used immunohistochemistry to identify cells and pathologies where SOCS3 expression might influence acute and chronic inflammatory responses in human tissues. Epitope and GFP tagged SOCS3 fusion proteins were localised predominantly in the nucleus of transfected cells and a validated anti SOCS3 antiserum revealed the expression of SOCS3 in the nucleus and cytoplasm of macrophages, endothelial and epithelial cells in a wide range of normal tissues in tissue microarrays (n = 31 different tissues). Nuclear SOCS3 was only seen in cells expressing a high level of the protein. Comparative immunostaining of acute, chronically and granulomatously inflamed human tissues revealed higher levels of nuclear and cytoplasmic SOCS3 expression in inflamed than in corresponding normal tissues, particularly in recruited leukocyte populations, but also in epithelia. The staining appeared more intense, suggesting higher expression levels, in areas where inflammation was more acute, consistent with the time course of SOCS3 induction described in vitro. Expression of SOCS3 protein by leucocytes and other cell types in tissue sections could be a useful marker of cells undergoing acute or chronic stimulation by cytokines in vivo.

Keywords SOCS3 · Transcription factor · Expression · Granuloma · Macrophage · Tissue · Inflammation

Introduction

The inflammatory response is driven by the release of inflammatory mediators and the recruitment of circulating leukocytes, which become activated at the site of inflammation and release further mediators. Generally, the inflammatory response is resolved by the release of endogenous anti-inflammatory mediators and the accumulation of intracellular negative regulatory factors (Nathan 2002). Failure to regulate inflammation adequately is important in autoimmunity and infection and may play a role in chronic diseases such as coronary artery disease, obesity and cancer (Lin and Karin 2007). Anti-cytokine therapies, such as anti-tumor necrosis factor-α, can successfully treat some chronic inflammatory diseases (Feldmann and Maini 2003).

Suppressor of cytokine signalling (SOCS) proteins are intracellular inhibitors of cytokine signalling that act in a classical negative feedback loop (Croker et al. 2004). SOCS3 may have profound effects on the regulation of immunity and inflammation by affecting the activation, development and homeostatic functions of all lineages involved in immune and inflammatory responses (O’Shea and Murray 2008). For example, SOCS3 limits the activities of the haematopoietic growth factors granulocyte...
colony stimulating factor (G-CSF) and granulocyte–macrophage colony stimulating factor (GM-CSF) (Croker et al. 2004). Administration of G-CSF in vivo mimics emergency granulopoiesis during infection. In SOCS3 conditional knockout mice, this process is grossly exacerbated, with neutrophil infiltration and destruction of liver, lung, muscle and spinal tissue, resulting from increased intensity and duration of G-CSF-induced Stat3 activation (Croker et al. 2003; Kimura et al. 2004).

Stimulation of macrophages with lipopolysaccharide (LPS) leads to the production of various cytokines including IL-1, TGF-β, IL-10, and IL-6, all of which upregulate SOCS3 expression (Dimitriou et al. 2008). Toll-like receptor (TLR) stimulation can also upregulate SOCS3 expression independently of cytokine induction (Dalpke et al. 2008). Indeed SOCS3 is one of the most abundantly induced proteins in LPS-stimulated macrophages (Yoshimura et al. 2007). SOCS3 then mediates feedback inhibition of LPS-induced macrophage activation (Berlato et al. 2002; Donnelly et al. 1999). SOCS3-transfected murine macrophages produce reduced levels of LPS-induced NO₂−, TNF-α, IL-6, and GM-CSF. The extent of this inhibition is similar to that seen in wild type cells treated with LPS and IL-10 (Berlato et al. 2002; Dimitriou et al. 2008). Accordingly, primary peritoneal SOCS3−/− macrophages exhibit impaired IL-10 regulation of LPS-induced NO₂− and TNF-α (Berlato et al. 2002). Macrophages from mice that lack SOCS3 expression in all haematopoietic and endothelial lineages produce more IL-6 following IL-1 stimulation (Wong et al. 2006). SOCS3 mRNA is induced rapidly following cytokine stimulation, being detectable within 20 min of IL-6 stimulation and declining to basal levels after 8 h (Larsen and Ropke 2002). Notwithstanding, SOCS3 has also been shown to positively regulate TLR4 signalling and M1 polarisation of macrophages in mouse and rat (Wang et al. 2010; Liu et al. 2008a, b).

SOCS1 and SOCS3 exert their negative feedback via several distinct mechanisms: (1) blocking JAK catalytic domain-STAT protein substrate interactions to terminate signal propagation; (2) competitively inhibiting JAK and STAT binding to phosphotyrosine-based docking sites on activated cytokine receptors, such as the shared cytokine subunit gp130; (3) targeting their binding partners for ubiquitination and proteasome degradation (Dimitriou et al. 2008). The SOCS3 protein inhibits signal transduction via various receptors, including the IL-6R, IFN-γR, GM-CSFR, IL-12 receptor β2, erythropoietin receptor, IL-27Rα, IL-31Rα, G-CSF receptor, and leptin receptor (Dimitriou et al. 2008; Dalpke et al. 2008; Xu et al. 2010).

However, SOCS3 does not bind or inhibit signalling via the IL-10R, explaining the divergent activities of the pro-inflammatory cytokine IL-6 and the immunoregulatory cytokine IL-10 following TLR stimulation (Dimitriou et al. 2008; Yoshimura et al. 2007). Induction of SOCS3 has been suggested as a means of immune evasion for bacteria, viruses and parasites, for example Mycobacterium bovis BCG (Imai et al. 2003; Dalpke et al. 2008). SOCS3 expression in dendritic cells (DCs) is important in regulating the production of cytokines able to direct naïve T-cell differentiation towards a T_{h}2 or a T_{reg} phenotype (Li et al. 2006; Dimitriou et al. 2008). Naïve T_{h} cells express high levels of SOCS3, which are transiently decreased after antigenic stimulation, allowing increased proliferation in response to IL-2. Both unstimulated and stimulated T_{reg} cells exhibit low SOCS3 levels (Dimitriou et al. 2008). A negative regulatory role for SOCS3 in IL-1 signalling has been observed in B-cells, in which SOCS3 negatively regulates IL-1R signalling pathways (Dimitriou et al. 2008).

SOCS3 knockout leads to placental defects, possible disturbances in intrahepatic erythropoiesis and embryonic lethality (Roberts et al. 2001; Marine et al. 1999; Larsen and Ropke 2002). Mice with a conditional deletion of the Socs3 gene in haematopoietic and endothelial cells die as young adults due to severe inflammatory lesions in the peritoneal and pleural cavities (Croker et al. 2008). Transgenic overexpression of SOCS3 also leads to embryonic lethality, while SOCS3 overexpression in T-cells leads to increased Th2 differentiation (Dalpke et al. 2008). SOCS3 mRNA expression has been identified in foetal liver, primarily during the stage of fetal liver erythropoiesis (Marine et al. 1999), and, at low levels, in adult mouse spleen, thymus and lung (Starr et al. 1997). A limited immunohistochemical study demonstrated SOCS3 expression in colonic epithelium and lamina propria leukocytes in biopsies from normal individuals and ulcerative colitis patients (Li et al. 2010).

The intracellular localisation of SOCS proteins has been controversial, with most authors reporting only a cytoplasmic localisation (Ding et al. 2003), although Lee and colleagues observed cytoplasmic and nuclear localisation (Lee et al. 2008). Nuclear localisation, however, seems inconsistent with SOCS proteins mediating their effects solely at the cell membrane (Dimitriou et al. 2008; Ding et al. 2003). To date detailed analysis of the expression pattern and intracellular localisation of SOCS proteins in human tissue samples has been limited by the availability of specific anti-human SOCS3 antisera that work on formalin fixed tissue.

Here we report the subcellular localisation of SOCS3 fusion proteins in transfected cells and we validate an anti-SOCS3 polyclonal rabbit serum and use it to determine the expression pattern of SOCS3 protein in a wide range of human tissues under normal and inflammatory conditions. By means of immunohistochemistry (IHC), we demonstrate both cytoplasmic and nuclear expression of SOCS3.

© Springer
in vitro and in vivo. SOCS3 expression in tissue samples may be a useful marker of cells undergoing acute and, to a lesser extent, chronic cytokine stimulation in vivo.

**Materials and methods**

**SOCS1 and SOCS3 fusion proteins**

Human SOCS1 and SOCS3 coding sequences were amplified by PCR and cloned into the expression plasmid pcDNA3.1, together with the GFP gene. The coding region of the recombinant plasmids was confirmed by DNA sequencing.

**IL-4 luciferase assay**

Murine TARC luciferase reporter plasmids, SOCS expression vectors and hCMV β-galactosidase plasmids were co-transfected into sub-confluent CHO cells using Genejuice® (Merck) in serum free Optimem medium (InVitrogen) (Liddiard et al. 2006). After 18 h, cells were stimulated with 20 ng ml⁻¹ Interleukin-4 (R&D Systems) for 6 h. Whole cell extracts were prepared in Reporter Lysis Buffer (Promega) and luciferase enzyme activity was determined using the Promega luciferase assay kit and β-galactosidase enzyme activity in the same lysates was assayed by measuring conversion of the colorimetric substrate chlorophenol red-β-D-galactopyranoside (Boeringer Mannheim) at 550 nm as described previously (Liddiard et al. 2006).

**Preparation of transfectants and western blot**

HEK293T cells were seeded into a six well plate and transfected with GFP, SOCS2 or SOCS3 expression plasmids using Genejuice® (Merck). Total cell lysates were prepared 36 h post transfection and western blots performed. Total protein (40 µg) was resolved on an SDS-PAGE gel and western blotted onto nitrocellulose (in duplicate). The blot was incubated with rabbit polyclonal anti-SOCS3 sera (ab16030 and ab53984) (ABCAM, Cambridge, UK) and bands detected with goat anti-rabbit horseradish peroxidase (HRP) (Biorad) and chemiluminescence (SuperSignal West Pico, Pierce). The blot was stripped and re-probed with rabbit anti-tubulin polyclonal antiserum (Cell Signaling Technology) to demonstrate equal protein loading in all lanes.

**Preparation of transfected paraffin wax cell blocks**

Cell blocks of HEK293 cells transiently transfected with SOCS2, SOCS3 or GFP were prepared using the Shandon Cytoblock® Cell Preparation System (Thermo Fisher Scientific, Massachusetts, USA) as per the manufacturer’s instructions and fixed in 4% formalin, followed by processing following standard histological techniques.

**Lipopolysaccharide stimulation and immunofluorescent staining of human peripheral blood mononuclear cells**

Human PBMCs were isolated from buffy coat preparations (National Blood Service, London, UK) using Ficoll-Paque plus according to manufacturer’s instructions (GE Healthcare, Little Chalfont, UK). Cells were plated in 8 well LabTek chamber slides (Nunc, Rochester NY) and cultured in X-Vivo 10 medium (Lonza, Wokingham, UK) plus 1% autologous serum for 7 days. Cells were stimulated for 4 h with 100 ng/ml LPS from Escherichia coli strain 055:B5 (Sigma–Aldrich, Gillingham, UK). After 4 h, medium was removed, cells were fixed in 4% paraformaldehyde for 15 min then permeabilised for 5 min in 0.25% Triton X-100/PBS. Non-specific binding was blocked for 30 min with blocking solution (PBS/0.1% Triton X-100/1% BSA/200 µg/ml human IgG). Anti-SOCS3 antibody (1:50 dilution, ab53984, Abcam) or isotype control (rabbit IgG, Jackson Immunoresearch) was added and cells stained overnight at 4°C. PE conjugated secondary antibody (1:200 dilution, goat anti-rabbit IgG, Jackson Immunoresearch) was added for 2 h at room temperature. Nuclei were counterstained for 5 min with DAPI (Sigma–Aldrich). Slides mounted with fluorescent mounting medium (Sigma–Aldrich). Images were captured using a Zeiss 510 META confocal microscope.

**Histological samples**

All tissue samples were obtained with full ethical approval from the National Research and Ethics Service (REC reference 04/Q1604/21). A wide range of normal human tissues (n = 31) were obtained from the Cellular Pathology Department, John Radcliffe Hospital, Oxford, UK, and used to construct tissue microarrays (core diameter 1 mm), using the MTA-1 manual arrayer (Beecher Instruments, Wisconsin, USA). Two cores from each donor block were taken to increase the sample area. Whole sections of tissue were similarly obtained.

**Antibodies and immunostaining**

The following primary antibodies were used: rabbit polyclonal against SOCS3 (ab53984, ABCAM, Cambridge, UK) and myeloperoxidase (AO398, Dako, Ely, UK); mouse monoclonal antibodies against DC-SIGN (clone DC28, R&D Systems, Minneapolis, USA); CD3 (clone LN10) and CD56 (clone 1B6, Leica Biosystems Newcastle Ltd, Newcastle, UK); mouse monoclonal antibodies against CD20
(clone L26), CD31 (clone JC70), CD61 (Y2/51), CD68 (clone PGM1) and glycophorin C (clone ret40f) were kindly donated by Prof. K. Gatter, Nuffield Department of Clinical Laboratory Sciences, Oxford, UK. Immunostaining was performed using standard techniques and a Bond Max™ immunostaining machine (Leica Biosystems Newcastle Ltd, Newcastle, U.K.). Heat mediated antigen retrieval was performed on all tissue sections using the high pH Epitope Retrieval 2 solution (Leica Microsystems, Wetzlar, Germany) for 20 min at 100°C. This was followed by a 5 min peroxidase block as per the manufacturers’ kit and instructions (Leica Microsystems, Wetzlar, Germany). For single labelled immunohistochemistry, the peroxidase/DAB Bond™ Polymer Refine Detection System (Leica Microsystems, Wetzlar, Germany) was used for visualisation. For double labelled immunohistochemistry, the peroxidase/DAB Bond™ Polymer Refine Detection System and alkaline phosphatase/fast red Bond™ Polymer AP Red Detection System (Leica Microsystems, Wetzlar, Germany) was used for visualisation. For double labelled immunohistochemistry, the peroxidase/DAB Bond™ Polymer Refine Detection System and alkaline phosphatase/fast red Bond™ Polymer AP Red Detection System (Leica Microsystems, Wetzlar, Germany) was used for visualisation. For double labelled immunohistochemistry, the peroxidase/DAB Bond™ Polymer Refine Detection System and alkaline phosphatase/fast red Bond™ Polymer AP Red Detection System (Leica Microsystems, Wetzlar, Germany) was used for visualisation.

Cell counting
Four 20× microscope fields were selected for counting for each tissue sample. Three full sections of each condition and corresponding normal tissue were used. The same areas were marked and counted on each slide.

Statistical analysis
The Minitab 15® statistics package (Minitab, State College, PA, USA) was used for all statistical analyses. Results from cell population counts were converted to proportions and recorded as a percentage e.g. percentage of CD68+ cells expressing SOCS3. Analysis of correlation was performed using the non-parametric Spearman’s rank correlation coefficient (r). This was achieved by performing a Pearson correlation coefficient on ranked data. To identify differences in population medians the Mann–Whitney U test was used.

Results
Antibody validation
To establish the specificity of the SOCS3 antibodies we performed western blots of GFP, SOCS2 and SOCS3 transfected cell lysates. Incubation with anti-SOCS3 ab53984 detected a single band of the correct molecular weight in SOCS3 transfected cell lysate and this band was not detected in lysates prepared from GFP or SOCS2 transfected cells (Fig. 1a, upper panel). Stripping the blots and re-probing with an anti-tubulin antibody demonstrated equal protein loading in each lane (Fig. 1a, middle panel). SOCS3 was not detected with a second commercially available SOCS3 antiserum (Fig. 1a, lower panel). Single labelled immunohistochemistry (IHC) using the anti-SOCS3 antibody ab53984 demonstrated positive staining in the SOCS3 CHO cell transfectants in formalin fixed paraffin blocks but did not identify protein expression in the GFP or SOCS2 CHO cell transfectants (Fig. 1b), thus confirming the specificity of the antibody. Of note immunohistochemical staining showed that SOCS3 protein was detectable in both the nuclear and cytoplasmic compartments of transfected cells. To characterise the antisera further, immunohistochemical staining of formalin fixed paraffin embedded human tonsil tissue was undertaken, using rabbit serum as a negative control. Positive cytoplasmic and nuclear staining of a range of mononuclear cells was seen with the anti-SOCS3 serum (Fig. 1c, upper panel), but not with normal rabbit serum (Fig. 1c, lower panel). Similarly, immunofluorescent staining of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells showed strong, predominantly nuclear staining (Fig. 1d, upper panel), while no staining was seen with an isotype control antibody (Fig. 1d, lower panel).

To establish the specificity of the SOCS3 antibodies we performed western blots of GFP, SOCS2 and SOCS3 transfected cell lysates. Incubation with anti-SOCS3 ab53984 detected a single band of the correct molecular weight in SOCS3 transfected cell lysate and this band was not detected in lysates prepared from GFP or SOCS2 transfected cells (Fig. 1a, upper panel). Stripping the blots and re-probing with an anti-tubulin antibody demonstrated equal protein loading in each lane (Fig. 1a, middle panel). SOCS3 was not detected with a second commercially available SOCS3 antiserum (Fig. 1a, lower panel). Single labelled immunohistochemistry (IHC) using the anti-SOCS3 antibody ab53984 demonstrated positive staining in the SOCS3 CHO cell transfectants in formalin fixed paraffin blocks but did not identify protein expression in the GFP or SOCS2 CHO cell transfectants (Fig. 1b), thus confirming the specificity of the antibody. Of note immunohistochemical staining showed that SOCS3 protein was detectable in both the nuclear and cytoplasmic compartments of transfected cells. To characterise the antisera further, immunohistochemical staining of formalin fixed paraffin embedded human tonsil tissue was undertaken, using rabbit serum as a negative control. Positive cytoplasmic and nuclear staining of a range of mononuclear cells was seen with the anti-SOCS3 serum (Fig. 1c, upper panel), but not with normal rabbit serum (Fig. 1c, lower panel). Similarly, immunofluorescent staining of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells showed strong, predominantly nuclear staining (Fig. 1d, upper panel), while no staining was seen with an isotype control antibody (Fig. 1d, lower panel).
Sub-cellular localisation of SOCS1 and SOCS3 in transfected CHO cells

In order to study the sub-cellular localisation of SOCS3 in living cells we transiently transfected CHO cells with SOCS1-GFP and SOCS3-GFP fusion proteins and observed them using confocal microscopy. Figure 2 shows the distribution of GFP alone, SOCS1-GFP and SOCS3-GFP in transfected CHO cells. GFP staining was distributed throughout the cell localising in both the nucleus and cytoplasm (Fig. 2a). SOCS1-GFP and SOCS3-GFP were localised predominantly in the nucleus, but were also present to a lesser extent in the cytoplasm (Fig. 2b, c). No fluorescence was detected in non-transfected cells (data not shown). We tested whether the presence of the GFP-tag would inhibit the ability of the SOCS protein to inhibit Jak/STAT signalling using the IL-4 inducible murine TARC promoter in transiently transfected CHO cells. As shown in Fig. 3, the presence of the GFP tag does not affect the ability of the SOCS1 or SOCS3 proteins to inhibit IL-4 signalling. However, we cannot state categorically that the presence of the GFP-tag does not alter other properties of the SOCS proteins, including subcellular localisation.

SOCS3 Immunohistochemistry on normal human tissue

In normal human tissues, SOCS3 immunopositivity was widespread with varying intensity. Cells with lower levels of expression demonstrated exclusively cytoplasmic SOCS3 expression, while appreciable levels of nuclear SOCS3 were visible in cells with higher cytoplasmic expression levels. SOCS3 expression could be seen in endothelial cells, macrophages, DCs, lymphocytes, neutrophils and in various epithelial cells in a wide range of normal human tissues, including tonsil, skin, testis (Fig. 4a), cervix, endometrium, fallopian tube (Fig. 4b), kidney, small and large intestine and lung (Table 1, Fig. 4). Epithelia that did not express SOCS3 included salivary gland, oesophagus, stomach pancreas, liver, adrenal, parathyroid and ovary. None of these tissues contained constitutive lymphoid infiltrates or significant numbers of other leucocytes. SOCS3 protein showed an interesting distribution in lymphoid tissue, including spleen, lymph node, tonsil and the small and large intestinal lamina propria. Strong immunopositivity was seen in the mantle and marginal zone of normal lymphoid cells, suggesting a role for SOCS3 in the regulation of immune responses. SOCS3 expression was also seen in the majority of leucocytes, particularly neutrophils, macrophages and lymphocytes, in inflammatory lesions, regardless of the phenotype of the infection. SOCS3 immunostaining appeared to be most intense in areas of acute inflammation, e.g., acute appendicitis (Fig. 5a), acutely inflamed radicular cysts, in crypt abscesses in ulcerative colitis (Fig. 5b), and in the central but not the peripheral parts of granulomas in various conditions (Fig. 5d–f). In these conditions, the
cells expressing high levels of SOCS3 appeared to be predominantly neutrophils, together with a smaller number of macrophages and other leucocytes. A higher level of SOCS3 expression than that of the corresponding normal tissue could also be seen in some epithelial and endothelial cells adjacent to areas of intense acute inflammation, for example crypt abscesses of ulcerative colitis (Fig. 5b) and inflamed radicular cysts.

In order to investigate the effects of inflammation on expression of SOCS3 by macrophages and DCs, the percentage of CD68^+ cells (macrophages/DCs) that expressed SOCS3 was determined in four 20× representative microscope fields in 3 cases of each of 7 pathological conditions with acute, chronic or granulomatous inflammation. Each individual inflammatory condition demonstrated a higher percentage of CD68^+ cells expressing SOCS3 than the corresponding normal tissue, with a significant p-value in the majority of cases (Table 2).

Discussion

In this study, we have used GFP-tagged forms of the human SOCS3 protein both to validate anti-SOCS3 antisera and investigate the subcellular localisation of SOCS3 protein. We demonstrate, by means of transfection immunohistochemical studies and immunofluorescent staining of LPS-stimulated peripheral blood mononuclear cells, that SOCS3 protein may be present in both the nucleus and cytoplasm, in keeping with a previous study using SOCS3 transfectants (Lee et al. 2008). In vivo, we show that nuclear SOCS3 immunostaining is seen only in cells with high levels of cytoplasmic expression, consistent with in vitro data demonstrating SOCS3 nuclear translocation only when its levels increase (Lee et al. 2008). The transfectants used in our study are likely to overexpress SOCS3, explaining the observed, predominantly nuclear localisation of the GFP-tagged SOCS3 protein in these experiments. There has been one previous limited immunohistochemical study of SOCS3 expression in human intestine (Li et al. 2010). While Li et al. describe cytoplasmic expression of SOCS3(Li et al. 2010), close examination of their immunohistochemical figures shows a predominantly cytoplasmic distribution in epithelial cells, but demonstrates a cytoplasmic and nuclear distribution of SOCS3 in leucocytes with morphological appearances of macrophages, DCs or lymphocytes in the large intestinal lamina propria, in agreement with our data.

Previous studies using mRNA analysis identified SOCS3 mRNA in normal mouse thymus, lung, spleen

![Fig. 3](tarc-luciferase-assay-in-cho-cells-showing-that-sox1-gfp-and-sox3-gfp-are-functional-cho-cells-2-x-10^6-were-transiently-transfected-with-500-ng-mtarc-luciferase-100-ng-hcmv-beta-galactosidase-200-ng-stat6-and-200-ng-of-the-indicated-sox-expression-vector-cells-were-transiently-transfected-for-18-h-then-stimulated-with-il-4-20-ng-ml^-1-for-6-h-before-harvest-in-luciferase-lysis-buffer-promega-results-are-expressed-as-luciferase-activity-normalized-for-beta-galactosidase-activity-and-are-representative-of-three-independent-experiments-and-data-are-presented-as-mean-sem)
| Tissue          | Morphology of SOCS3-expressing cells | Other/comments                                                                 |
|-----------------|--------------------------------------|-------------------------------------------------------------------------------|
| Tonsil          | Macrophages/DCs Positive, Negative   | Positive in germinal centre B-cells, tingible body macrophages, sinus and interdigitating dendritic cells; very weakly positive on some other lymphocytes. |
| Lymph node      | Positive Sinus endothelial cells positive | Not applicable Positive in germinal centre B-cells, tingible body macrophages and interdigitating dendritic cells; very weakly positive on some other lymphocytes. | |
| Spleen          | Strongly positive Weakly positive, particularly sinus endothelium | Not applicable | Lymphocytes negative |
| Thymus          | Strongly positive Weakly positive | Strongly positive Almost all thymocytes negative, occasional cells very weakly positive |
| Skin            | Occasionally positive Vascular endothelial cells positive | Weakly positive, particularly appendages Scattered leucocytes are occasionally positive. | |
| Salivary gland  | Positive Negative | Lymphocytes and plasma cells largely negative, except intraepithelial lymphocytes, which are strongly positive. |
| Oesophagus      | Positive Strongly positive | Negative | |
| Stomach         | Positive Positive | Negative | |
| Small bowel     | Positive Strongly positive | Negative | |
| Appendix        | Positive Negative or occasionally weakly positive | Positive Lymphocytes largely negative. |
| Colon           | Positive Weakly positive | Weakly positive | |
| Liver           | Kupffer cells negative Negative | Negative Occasional positive leucocytes Some islet cells positive. |
| Gallbladder     | Occasional positive cells Weakly positive | Weakly positive | |
| Pancreas        | Positive Weakly positive | Negative | |
| Lung            | Alveolar macrophages, positive Positive | Positive in both type I and type II pneumocytes | |
| Thyroid         | Weakly positive Weakly positive | Weakly positive | Scattered weakly positive leucocytes |
| Parathyroid     | Negative Weakly positive | Negative | |
| Adrenal         | Strongly positive Negative | Negative | |
| Kidney          | Not applicable Negative | Tubular epithelium positive particularly in atrophic tubules. | |
| Bladder         | Positive Weakly positive | Strongly positive Scattered stromal leucocytes positive | |
| Prostate        | Negative Negative | Very weakly positive Spermatogenic cells strongly positive | |
| Testis          | Positive Negative | Positive | |
| Breast          | Negative Positive | Negative | |
| Cervix          | Positive Negative | Very weakly positive Intraepithelial lymphocytes of endocervix strongly positive, Scattered stromal leucocytes occasionally weakly positive. | |
(Starr et al. 1997) and foetal liver (Marine et al. 1999), and in human T-cells, monocytes and macrophages in vitro (Isomaki et al. 2007; Rakshit et al. 2006). Using immunohistochemistry we were able not only to confirm the expression of SOCS3 protein in normal human adult thymus, lung, liver and spleen, but also to identify the major positive cell types as macrophages, immature myeloid DCs and endothelial cells. Additionally, in normal tissues, SOCS3 is expressed by neutrophils, some B and T-lymphocytes, occasional natural killer cells and many types of epithelium. Our demonstration of SOCS3 expression by epithelia at a number of sites is also in keeping with the study by Li et al. in which the authors show expression of SOCS3 by colonic epithelial cells (Li et al. 2010). The figures in their study demonstrate SOCS3 expression by lamina propria leucocytes with morphological appearances suggesting that they might be macrophages, DCs or lymphocytes, although the authors do not comment on expression by these cell types or determine their identity. However, the SOCS3 expression pattern is consistent with the pattern we describe here, both in normal colon and in ulcerative colitis.

While epithelia adjacent to lymphoid aggregates or leucocytic infiltrates (e.g., small and large intestine, tonsil, cervix) express SOCS3, epithelia with few adjacent leucocytes are generally SOCS3 negative, e.g., salivary gland, oesophagus, stomach, pancreas and liver. Many epithelia express cytokine receptors, for example for TNF-α, IL-1 and IL-6 (Fritz et al. 2008), which are known to induce SOCS3. Epithelia adjacent to lymphoid aggregates or leucocytic infiltrates may be subject to repeated stimulation by these cytokines, leading to the induction of SOCS3 expression detectable by IHC.

SOCS3 shows an interesting distribution in lymphoid tissue, including spleen, lymph node, tonsil and the small and large intestinal lamina propria. Strong immunopositivity is seen in tingible body macrophages, interdigitating DCs, DCs in sinuses and germinal centre B lymphocytes. Mantle/marginal zone B and paracortical T lymphocytes show little SOCS3 expression. Data from mouse studies indicate only very low levels of SOCS3 expression in progenitor B cells with a gradual increase in SOCS3 levels as B cells become more mature (Le et al. 2007). SOCS3 can inhibit focal adhesion kinase activation, preventing B cell adhesion to VCAM-1, increasing B-cell motility (Le et al. 2007). It is likely that germinal centre B-cells require significant motility to allow interaction with follicular DCs and T-cells. Mantle/marginal zone B-cells may remain in lymphoid areas for longer periods, thus requiring less motility and possibly explaining their lower levels of SOCS3 expression. An alternative explanation is discrepancies between the human and mouse immune systems in patterns of SOCS3 expression. Our observation of minimal

| Tissue                      | Macrophages/DCs | Endothelial cells | Epithelial cells | Other/Comments                  |
|-----------------------------|-----------------|-------------------|------------------|---------------------------------|
| Endometrium                 | Positive        | Negative          | Weakly positive  | Scattered stromal cells weakly positive | scant leucocytes present, some of which including CD56
| Fallopian tube              | None seen       | Positive          | Negative         | Weakly positive, occasional lymphocytes, some of which are positive. |
| Ovary                      | Positive        | Positive          | Positive         | Stromal cells strongly positive  |
| Amniotic membrane           | Positive        | Positive          | Negative         | Syncytiotrophoblast positive    |
| Placenta                    | Negative        | Negative          | Negative         | Syncytiotrophoblast & cytrophoblast positive |
expression of SOCS3 by paracortical T-lymphocytes appears incongruous with the observation in vitro that naive T<sub>h</sub> cells express high levels of SOCS3, which are transiently decreased after antigenic stimulation, allowing increased proliferation in response to IL-2 (Dimitriou et al. 2008). One possibility is that the lymphoid tissue we examined contained predominantly T lymphocytes responding to antigen and thus undergoing activation/proliferation, with concomitantly decreased SOCS3 levels. Alternatively, there may be differences between the mouse immune system, in which much previous work has been done (Dimitriou et al. 2008), and the human immune system.

In the thymus, cells mediating positive and negative selection, such as macrophages, DCs and epithelial cells, showed high levels of SOCS3 expression. Little expression was seen in thymocytes, in keeping with a report showing that SOCS3 conditional knockout mice demonstrate normal T-cell development in the thymus, suggesting SOCS3 may not play a crucial role in thymocytes (Chen et al. 2006).

Cells expressing SOCS3 in normal tissues may be subject to cytokine stimulation. At sites where few cytokines are likely to be present, there may be some other, as yet undetermined mechanism of SOCS3 induction causing regulation of cytokine or TLR-mediated activation, possibly to prevent inappropriate induction of an inflammatory or immune response. Tissue macrophages or DCs may, for example, express SOCS3 to prevent them producing pro-inflammatory/immune cytokines and/or expressing crucial co-stimulatory molecules that might otherwise induce an immune or inflammatory response, with the inherent risks of breaking immunological tolerance or causing inflammatory damage (Hart 1997). Similarly, certain endothelia, particularly lymph node sinus endothelium and possibly some small blood vessel endothelium, may present antigen to lymphocytes to induce immunological tolerance (Soilleux et al. 2002). SOCS3 may be important at these sites in preventing the production of pro-inflammatory/immune cytokines. If such cells did present antigen to T lymphocytes, they might induce tolerance rather than immunity in these lymphocytes.

In bone marrow, cells of the granulocytic and monocytic lineage express high levels of SOCS3 (Fig. 4c), in keeping with data from SOCS3 conditional knockout mice demonstrating that SOCS3 is necessary to limit the activities of the haematopoietic growth factors G-CSF and GM-CSF (Croker et al. 2004; Croker et al. 2003; Kimura et al. 2004). Expression of SOCS3 by myeloid cells may also explain the appreciable levels of SOCS3 mRNA previously detected in foetal liver (Marine et al. 1999). Mutations in the tyrosine kinase JAK2 are identified in the majority of patients with myeloproliferative neoplasms, such as essential thrombocythaemia, a chronic proliferative neoplasm of megakaryocytes. JAK2, particularly when constitutively activated by mutation, phosphorylates a tyrosine residue in SOCS3 to inactivate it and escape its inhibition (Elliott et al. 2009; Hookham et al. 2007). Our demonstration for the first time of SOCS3 expression by normal megakaryocytes provides additional evidence for this mechanism.

In keeping with our data showing high levels of SOCS3 expression in LPS-stimulated peripheral blood mononuclear cells, particularly cells morphologically resembling macrophages, we observed a marked increase in SOCS3 expression in inflamed tissues, in many types of leucocyte, particularly neutrophils, macrophages and lymphocytes, as well as in epithelia, endothelia and fibroblasts. Given our observation of high levels of SOCS3 expression in maturing myeloid cells in bone marrow, it is not possible to determine whether there is rapid induction of neutrophil SOCS3 expression at sites of inflammation following their recruitment to these sites or whether neutrophils that constitutively express SOCS3 are recruited to the inflamed site. Our striking observation of the significant accentuation of SOCS3 expression in the centre of granulomas compared with the peripheral parts. It is likely that there is both a higher level of cytokines, such as IL-6, and of microbial products at the centre of the granuloma, causing increased levels of SOCS3 induction via both cytokine receptors and TLRs. The relatively short half-life of SOCS3 would mean that its expression relied on repeated or continuous induction, mirroring local cytokine or microbial product levels. Following IL-6 stimulation of myeloid cell lines, mRNA from SOCS-3 is detectable within 20 min,

![SOCS3 expression in inflamed human tissues.](Color figure online)
declining to basal levels after 8 h (Larsen and Ropke 2002). Our observation of more intense immunostaining, suggesting higher SOCS3 expression levels, in acute than chronic or granulomatous inflammation is also consistent with the time course of SOCS3 induction, as well as possibly being related to higher cytokine levels in acute inflammation.

In summary, we have demonstrated both cytoplasmic and nuclear localisation of the regulatory protein SOCS3 and have performed the first detailed expression study on SOCS3 by means of immunohistochemistry on human tissues. Commensurate with its induction by a range of cytokines, with a rapid time course of induction and subsequent rapid downregulation, a very significant increase in
Table 2  Inflammatory conditions, their normal counterparts and changes in percentage of CD68+ cells expressing SOCS3 in various inflammatory conditions

| Inflammatory Condition          | Mean % CD68+ cells expressing SOCS3 (counted in 4 fields) (%) | Type of Inflammation                  | Corresponding Normal Tissue            | Mean % CD68+ cells expressing SOCS3 (counted in 4 fields) (%) | % CD68+ cells expressing SOCS3 in inflamed compared with normal tissue |
|---------------------------------|---------------------------------------------------------------|---------------------------------------|----------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------|
| Lymph node sarcoidosis          | 62.35                                                         | Granulomatous                         | Normal lymph node                      | 27.42                                                         | ↑ p = 0.0014                                                          |
| Crohn’s Disease                 | 43.10                                                         | Granulomatous                         | Normal colon                           | 11.04                                                         | ↑ p < 0.0001                                                          |
| UC                              | 40.03                                                         | Acute-on-chronic                      | Normal colon                           | 11.04                                                         | ↑ p < 0.0001                                                          |
| Acute appendicitis              | 32.69                                                         | Acute                                 | Normal colon                           | 11.04                                                         | ↑ p = 0.0020                                                          |
| Hidradenitis suppurativa        | 24.60                                                         | Granulomatous                         | Normal skin                            | 18.81                                                         | / p = 0.1572                                                          |
| Radicular cyst                  | 40.65                                                         | Acute-on-chronic                      | Benign fibroepithelial polyp           | 34.33                                                         | / p = 0.3123                                                          |
| Temporal arteritis              | 53.29                                                         | Granulomatous                         | Normal temporal artery                 | 31.46                                                         | ↑ p = 0.0239                                                          |

expression at sites of inflammation, particularly in areas where the inflammation is acute and/or cytokines are present at highest levels. This makes SOCS3 a potential marker of sites at which there are significant levels of cytokines and it may be a more stable and useful marker of ongoing inflammation than the cytokines themselves.

Acknowledgments  Work in the laboratory of DRG is funded by the British Heart Foundation. MA was the recipient of a Wellcome Trust Cardiovascular Initiative PhD studentship. ES is supported by a grant from the Oxford University Medical Research Fund.

Conflicts of interest  The authors have no conflicts of interest to declare.

Open Access  This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

Berlato C, Cassatella MA, Kinjo Y, Gatto L, Yoshimura A, Bazzoni F (2002) Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of il-10 on lipopolysaccharide-induced macrophage activation. J Immunol 168(12):6404–6411
Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O’Shea JJ (2006) Selective regulatory function of socs3 in the formation of il-17-secreting t cells. Proc Natl Acad Sci U S A 103(21):8137–8142. doi:10.1073/pnas.0600661103
Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS (2003) Socs3 negatively regulates il-6 signaling in vivo. Nat Immunol 4(6):540–545. doi:10.1038/nri931
Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse LA, Sutherland KD, Hartley L, Williams E, Zhang JG, Hilton DJ, Nicola NA, Alexander WS, Roberts AW (2004) Socs3 is a critical physiological negative regulator of g-csf signalling and emergency granulopoiesis. Immunity 20(2):153–165
Croker BA, Kiu H, Nicholson SE (2008) Socs regulation of the jak/stat signalling pathway. Semin Cell Dev Biol 19(4):414–422. doi:10.1016/j.semcdb.2008.07.010
Dalpke A, Heeg K, Bartz H, Baetz A (2008) Regulation of innate immunity by suppressor of cytokine signaling (socs) proteins. Immunobiology 213(3–4):225–235. doi:10.1016/j.imbio.2007.10.008
Dimitriou ID, Clemenza L, Scatter AJ, Chen G, Guerra FM, Rottapel R (2008) Putting out the fire: Coordinated suppression of the innate and adaptive immune systems by socs1 and socs3 proteins. Immunol Rev 224:265–283. doi:10.1111/j.1600-065X.2008.00659.x
Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, Bromberg JS (2003) Suppressor of cytokine signaling 1 inhibits il-10-mediated immune responses. J Immunol 170(3):1383–1391
Donnelly RP, Dickensheets H, Finbloom DS (1999) The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19(6):563–573. doi:10.1089/107999099313695
Elliott J, Suessmuth Y, Scott LM, Nahlik K, McMullin MF, Constantinescu SN, Green AR, Johnston JA (2009) Socs3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant jak2 kinases. Haematologica 94(4):576–580. doi:10.3324/haematol.2008.002352
Feldmann M, Maini RN (2003) Lasker clinical medical research award. Tnf defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9(10):1245–1250. doi:10.1038/nm939
Fritz JH, Le Bourhis L, Magalhaes JG, Philpott DJ (2008) Innate immune recognition at the epithelial barrier drives adaptive immunity: Apcs take the back seat. Trends Immunol 29(1):41–49. doi:10.1016/j.it.2007.10.002
Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90(9):3245–3287
Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, Percy MJ, McMullin MF, Constantinescu SN, Johnston JA (2007) The myeloproliferative disorder-associated jak2 v617f mutant escapes negative regulation by suppressor of cytokine signaling 3. J Immunol 178(9):5081–5089. doi:10.4049/jimmunol.178.9.5081
Imai K, Kurita-Ochiai T, Ochiai K (2003) Mycobacterium bovis bacillus calmette-guerin infection promotes socs induction and inhibits ifn-gamma-stimulated jak/stat signaling in j774 macrophages. FEMS Immunol Med Microbiol 39(2):173–180
Isomaki P, Alanara T, Isohanni P, Lagerstedt A, Korpela M, Moilanen T, Visakorpi T, Silvennoinen O (2007) The expression of socs is altered in rheumatoid arthritis. Rheumatology (Oxford) 46(10):1538–1546. doi:10.1093/rheumatology/kem198

Kimura A, Kinjyo I, Matsumura Y, Mori H, Mashima R, Harada M, Chien KR, Yasukawa H, Yoshimura A (2004) Socs3 is a physiological negative regulator for granulocyte colony-stimulating factor receptor signaling. J Biol Chem 279(8):6905–6910. doi:10.1074/jbc.C300496200

Larsen L, Ropke C (2002)Suppressors of cytokine signalling: Socs. APMIS 110(12):833–844

Le Y, Zhu BM, Harley B, Park SY, Kobayashi T, Manis JP, Luo HR, Yoshimura A, Hennighausen L, Silberstein LE (2007) Socs3 protein developmentally regulates the chemokine receptor cxcr4-fak signaling pathway during βlymphopoiesis. Immunity 27(5):811–823. doi:10.1016/j.immuni.2007.09.011

Lee KH, Moon KJ, Kim HS, Yoo BC, Park S, Lee H, Kwon S, Lee ES, Yoon S (2008) Increased cytoplasmic levels of cis, socs1, socs2, or socs3 are required for nuclear translocation. FEBS Lett 582(15):2319–2324. doi:10.1016/j.febslet.2008.05.039

Li Y, Chu N, Rostami A, Zhang GX (2006) Dendritic cells transduced with socs-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 TH cell differentiation in vitro and in vivo. J Immunol 177(3):1679–1688

Li Y, de Haar C, Chen M, Deuring J, Gerrits MM, Smits R, Xia B, Kuipers EJ, van der Woude CJ (2010) Disease-related expression of the il6/stat3/socs3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 59(2):227–235. doi:10.1136/gut.2009.184176

Liddiard K, Welch JS, Lozach J, Heinz S, Glass CK, Greaves DR (2006) Interleukin-4 induction of the cc chemokine tarc (ccl17) in murine macrophages is mediated by multiple stat6 sites in the tarc gene promoter. BMC Mol Biol 7:45. doi:10.1186/1471-2199-7-45

Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117(5):1175–1183. doi:10.1172/JCI31537

Liu X, Zhang Y, Yu Y, Yang X, Cao X (2008a) Socs3 promotes dlr4 response in macrophages by feedback inhibiting tgf-beta1/smad3 signaling. Mol Immunol 45(5):1405–1413. doi:10.1016/j.molimm.2007.08.018

Liu Y, Stewart KN, Bishop E, Marek CJ, Kluth DC, Rees AJ, Wilson HM (2008b) Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 180(9):6270–6278

Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, Ihle JN (1999) Socs3 is essential in the regulation of fetal liver erythropoiesis. Cell 98(5):617–627

Nathan C (2002) Points of control in inflammation. Nature 420(6917):846–852. doi:10.1038/nature01320

O’Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28(4):477–487. doi:10.1016/j.immuni.2008.03.002

Rakshit DS, Ly K, Sengupta TK, Nestor BJ, Sculco TP, Ivashkiv LB, Purdue PE (2006) Wear debris inhibition of anti-osteoestrogenic signaling by interleukin-6 and interferon-gamma Mechanistic insights and implications for periprosthetic osteolysis. J Bone Joint Surg Am 88(4):788–799. doi:10.2106/JBJS.E.00711

Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, Nicola NA, Metcalf D, Hilton DJ, Alexander WS (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 98(16):9324–9329. doi:10.1073/pnas.161271798

Soilleux EJ, Morris LS, Rushbrook S, Lee B, Coleman N (2002) Expression of human immunodeficiency virus (hiv)-binding lectin dc-sign: consequences for hiv infection and immunity. Hum Pathol 33(6):652–659

Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387(6636):917–921

Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, Liang YM, Han H (2010) Notch signaling determines the m1 versus m2 polarization of macrophages in antitumor immune responses. Cancer Res 70(12):4840–4849. doi:10.1158/0008-5472.CAN-10-0269

Wong PK, Egan PJ, Croker BA, O’Donnell K, Sims NA, Drake S, Kiu H, McManus EJ, Alexander WS, Roberts AW, Wicks IP (2006) Socs-3 negatively regulates innate and adaptive immune mechanisms in acute il-1-dependent inflammatory arthritis. J Clin Invest 116(6):1571–1581. doi:10.1172/JCI25660

Xu Y, Kershaw NJ, Luo CS, Soo P, Pocock MJ, Czabotar PE, Hilton DJ, Nicola NA, Garrett TP, Zhang JG (2010) Crystal structure of the entire ectodomain of gp130: Insights into the molecular assembly of the tall cytokine receptor complexes. J Biol Chem. doi:10.1074/jbc.C110.129502

Yoshimura A, Naka T, Kubo M (2007) Socs proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7(6):454–465. doi:10.1038/nri2093